NCT04743622View on ClinicalTrials.gov

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

June 23, 2020

Study Completion Date

September 13, 2020

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Monoprost

preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes

DRUG

Xalatan

preserved latanoprost 1 drop once a day for 12 weeks to target eyes

Trial Locations (1)

13497

CHA University Bundang Medical Center, Seongnam

All Listed Sponsors
collaborator

Samil Pharmaceutical Co., Ltd.

INDUSTRY

lead

CHA University

OTHER

NCT04743622 - Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost | Biotech Hunter | Biotech Hunter